Dipirone, also known by the commercial name of Novaralgina, is an anti -pitched pain reliever and analgesic in many countries, including Brazil to relieve headache and fever. However, it is prohibited in the United States and in various countries in Europe, as well as in other countries such as Japan and Australia. This prohibition generates many doubts, especially in the regions in which medicine is free and considered safe and effective.
The drug is both popular in Brazil and, according to the National Health Surveillance Agency (Anvisa), over 215 million doses of this medicine were marketed in the country only in 2022.
Why is the Dipirone prohibited in different countries?
The main reason for this restriction is worried about a rare but potentially fatal adverse effect: agranulocytosis.
This serious condition causes an acute and sudden fall of the number of granulocytes, a type of white blood cells for the immune system. This serious reduction makes the body vulnerable to serious infections, which can be fatal.
Although the incidence of agranulocytosis induced by Dipirone is considered rare (estimates range from 1 to 1,000 to 1 on 10,000 or up to 1,000 users, depending on the study and the population), the severity of the condition caused health regulation agencies in some countries to adopt a more cautious position.
For these organs, the risk, however small, does not justify the marketing without restrictions of the Dipirone, in particular considering the existence of analgesic and antipyretic alternatives with security profiles sold in pharmacies.
In addition to Novalgina, other popular remedies that Dipirone have in its composition are Dorflex and Neosalde.
Source: Terra

Ben Stock is a lifestyle journalist and author at Gossipify. He writes about topics such as health, wellness, travel, food and home decor. He provides practical advice and inspiration to improve well-being, keeps readers up to date with latest lifestyle news and trends, known for his engaging writing style, in-depth analysis and unique perspectives.